{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:07:28Z","timestamp":1789240048394,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Internal grant from St. Marianna University School of Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40291-025-00807-4","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T08:44:39Z","timestamp":1756716279000},"page":"839-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Tumor DNA Profiling Reveals Genomic Evolution in Recurrent Gastric or Gastroesophageal Junction Cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Ryohei","family":"Kawabata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2847-7105","authenticated-orcid":false,"given":"Hiroyuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Akamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yabusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"807_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, Van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"807_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"807_CR3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"807_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725\u201330.","journal-title":"N Engl J Med"},{"key":"807_CR5","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"807_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10120-011-0101-x","volume":"15","author":"K Shitara","year":"2012","unstructured":"Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, et al. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer. 2012;15:245\u201351.","journal-title":"Gastric Cancer"},{"key":"807_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10120-018-0815-0","volume":"21","author":"K Nishikawa","year":"2018","unstructured":"Nishikawa K, Tsuburaya A, Yoshikawa T, Takahashi M, Tanabe K, Yamaguchi K, et al. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: xparts-i trial. Gastric Cancer. 2018;21:811\u20138.","journal-title":"Gastric Cancer"},{"key":"807_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.bjc.6602336","volume":"92","author":"HJ Kang","year":"2005","unstructured":"Kang HJ, Chang HM, Kim TW, Ryu M-H, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer. 2005;92:246\u201351.","journal-title":"Br J Cancer"},{"key":"807_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020;11:346.","journal-title":"Cell Death Dis"},{"key":"807_CR10","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","volume":"24","author":"JI Odegaard","year":"2018","unstructured":"Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res. 2018;24:3539\u201349.","journal-title":"Clin Cancer Res"},{"key":"807_CR11","unstructured":"Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017.PO.17.00011."},{"key":"807_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23336","volume":"6","author":"J Matsubara","year":"2023","unstructured":"Matsubara J, Mukai K, Kondo T, Yoshioka M, Kage H, Oda K, et al. First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open. 2023;6: e2323336.","journal-title":"JAMA Netw Open"},{"key":"807_CR13","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2024.42.16_suppl.3137","volume":"42","author":"R Hayashi","year":"2024","unstructured":"Hayashi R, Matsubara J, Mukai K, Yoshioka M, Kage H, Oda K, et al. Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study. J Clin Oncol. 2024;42:3137.","journal-title":"J Clin Oncol"},{"key":"807_CR14","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","volume":"24","author":"S Kato","year":"2018","unstructured":"Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res. 2018;24:6248\u201356.","journal-title":"Clin Cancer Res"},{"key":"807_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","volume":"18","author":"DVT Catenacci","year":"2017","unstructured":"Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1467\u201382.","journal-title":"Lancet Oncol"},{"key":"807_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","volume":"30","author":"BG Sullivan","year":"2023","unstructured":"Sullivan BG, Lo A, Yu J, Gonda A, Dehkordi-Vakil F, Dayyani F, et al. Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis. Ann Surg Oncol. 2023;30:278\u201384.","journal-title":"Ann Surg Oncol"},{"key":"807_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10120-016-0599-z","volume":"20","author":"K Shoda","year":"2017","unstructured":"Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. 2017;20:126\u201335.","journal-title":"Gastric Cancer"},{"key":"807_CR18","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-24-2763","volume":"31","author":"F Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam F, Raghav KPS, Sweeney CJ, Swanton C, Spigel DR, Bose R, et al. ctDNA analysis in ERBB2-amplified colorectal cancer: biomarker analysis of the MyPathway trial. Clin Cancer Res. 2025;31:2935\u201344.","journal-title":"Clin Cancer Res"},{"key":"807_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3912","author":"G Vandekerkhove","year":"2025","unstructured":"Vandekerkhove G, Murtha AJ, M\u00fcller DC, Stephenson M, Rostin K, Munzur AD, et al. ERBB2\/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3912.","journal-title":"Clin Cancer Res"},{"key":"807_CR20","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1158\/1078-0432.CCR-18-3389","volume":"25","author":"G Siravegna","year":"2019","unstructured":"Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25:3046\u201353.","journal-title":"Clin Cancer Res"},{"key":"807_CR21","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/JCO.23.02010","volume":"42","author":"A Ohba","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J Clin Oncol. 2024;42:3207\u201317.","journal-title":"J Clin Oncol"},{"key":"807_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21:751\u20139.","journal-title":"Nat Med"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00807-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:53:04Z","timestamp":1761947584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00807-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00807-4","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"1 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroyuki Takeda and Yu Sunakawa have received honoraria for speaking engagements from Guardant Health, Inc. Ryohei Kawabata, Atsushi Ishiguro, Shinichi Nishina, Masazumi Takahashi, Shuhei Suzuki, Takahisa Suzuki, Jin Matsuyama, Yasufumi Otsuki, Yusuke Akamaru, Naoki Takegawa, Takashi Nomura, Yosuke Kito, Hiroshi Yabusaki, Yuji Negoro, Akitaka Makiyama, Masato Nakamura, and Masaki Takahashi have no conflicts of interest that are directly relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved by the institutional review board of each participating site. Specifically, the Institutional Review Board of St. Marianna University School of Medicine approved the study on 21 January, 2021 (approval number: 5085). The study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all participants for study participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Written informed consent was obtained from all participants for publication of the results.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing requests should be directed to the corresponding author along with the research proposal. The decision to share the requested data will be made in accordance with ethical guidelines by the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RK, AI, SN, MT, SS, TS, JM, YO, YA, NT, TN, YK, HY, YN, AM, and MN contributed to the investigation and writing (review and editing). HT was responsible for conceptualization, investigation, writing (original draft), writing (review and editing), and funding acquisition. MT handled the data curation, methodology, formal analysis, and writing (review and editing). YS took part in project administration, investigation, writing (review and editing), and supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}